Silence Therapeutics Share Discussion Threads

[kreature] 23/9/2021 09:15

There you go. I expect a thank you.

[kreature] 21/9/2021 14:26

You were supposed to mark my post as the low. Now look what you’ve done.

[volsung] 20/9/2021 09:19

Hopefully a solid bounce from here

[1gw] 09/9/2021 21:08

I bought some back at the end of August in the 570's.

[volsung] 09/9/2021 16:04

A bit premature there it seems lol

[volsung] 08/9/2021 16:05

Bought a few more for 542.1p

[frndlyfire] 26/8/2021 11:52

With k back i am wondering if i made the wrong decision lightening the load at £6! This remains my largest holding, at least now i can be unhappy whichever way the share price moves :)

[1gw] 26/8/2021 08:47

It is uncanny, k.

[kreature] 25/8/2021 19:54

I see that my last post did the trick, again.

[1gw] 25/8/2021 14:04

And now I can sell at more than £6. Opaque as ever.

[wilko14] 25/8/2021 10:20

Or someone is trying to keep the price at a 60 day average to ensure better buyout terms…

[1gw] 25/8/2021 08:03

But there you go. 12 shares says it's back over £6 this morning! Don't suppose it will last, but you never know with SLN.

[1gw] 24/8/2021 22:11

My guess is a buyer who was mopping up shares around 600p has stopped or paused and the price is drifting down a bit given it seems unlikely we'll get Takeda or clinical news imminently and the next obvious catalyst is not until 21st October (R&D day). I think the news on clinical delay and neutral positioning on Takeda merited a bit of a sell-off (although mitigated a bit by the news on R&D day) and I was surprised it closed above 600p on 12th Aug. The relative valuation argument still applies, but the news on SLN itself was (IMO) unambiguously disappointing.

I sold some more myself to release funds for other things, and may sell again, but will consider topping back up nearer to the R&D day.

[kreature] 24/8/2021 21:17

500 magnet first station stop?

[wilko14] 24/8/2021 17:38

Really poor slide on no news, but then again we have been here before…

[1gw] 12/8/2021 20:12

Nice to see it close above £6 despite some apparent selling pressure. It has felt to me for some time like someone is backstopping it around £6, perhaps an institution or big private investor prepared to add at that level.

I took some off the table this morning, given what I felt was a generally disappointing update, although I was pleased later on with the way the Takeda position was spun in the call - still a chance it seems that after going through their internal review processes Takeda engage again this year.

And I like the possibilities of the R&D day in terms of providing a catalyst for further share price appreciation ahead of clinical data. Plus we also have the likelihood of additional data from the SLN124 healthy volunteer study at the ASH conference in December.

[1gw] 12/8/2021 13:44

Takeda - on the call SLN clarified that Takeda are now evaluating the data from the trial on Takeda's target and they (Takeda) have an option to follow up with a licensing deal for that target. So it's wait and see...

[1gw] 12/8/2021 11:52

Takeda update - didn't get that far at first read this morning, hidden in the bowels of the report:

"Our activities under the Technology Evaluation Agreement were effectively complete as of June 30, 2021. We may negotiate to enter into an exclusive follow-on license and collaboration agreement covering the Takeda target at some point in the future."

Somewhat indeterminate and underwhelming.

Still, how about that balance sheet, k? £71m in cash & equivalents at 30th June, with just £10m in term deposits.

[1gw] 12/8/2021 08:14

Cheer up, k. 4 cohorts of SLN360 recruited, topline data put back only 1Q and still guiding to starting Phase 2 in 2022. Delay to SLN124 more material, but it is the less exciting asset and in the past delays to that programme haven't been particularly negative for the shareprice have they, if you remember the first dosing saga?

And it's good to have an R&D day to look forward to, in particular more detail on the pipeline beyond the 2 clinical assets: "We look forward to discussing the continued progress of our SLN360 and SLN124 clinical programs as well as our broader pipeline in more detail"

But undeniably disappointing (if not entirely unexpected given their track record) to have the delays.

[wilko14] 12/8/2021 07:55

Yawn. Very poor days for RNAI investors

[kreature] 12/8/2021 07:55

Can take a 100p off the share price to reflect that imo

[1gw] 12/8/2021 07:17

Closest to the "depressing" outcome then, with delays to the clinical programmes. No news on Takeda yet so we can hope for an update in the webcast And an R&D day to look forward to in October to take the edge off the clinical delay.

[1gw] 11/8/2021 16:03

Twas the night before Christmas and...

Don't know what to expect from tomorrow. Could be a damp squib focusing on 1H financials and reiterating timelines for the ongoing trials. Or it could be fireworks with announcement of a big Takeda deal. Or it could be depressing with news that there won't be a Takeda deal and the dates for the release of further trial data are being pushed back into 2022.

[volsung] 09/8/2021 16:25

Bought a few more for the SIPP